Can-Fite BioPharma (CANF) EBITDA Margin Growth (3y) (2018 - 2023)
Can-Fite BioPharma (CANF) EBITDA Margin Growth (3y) (2018 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -537.00 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -1,934.00 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7,261.00 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 9,003.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 30,461.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -2,649.00 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -11,254.00 |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 118,544.00 |
| Sep 30, 2023 | 22,335.00 |
| Jun 30, 2023 | 96,774.00 |
| Mar 31, 2023 | 77,592.00 |
| Dec 31, 2022 | 149,233.00 |
| Sep 30, 2022 | -101,900.00 |
| Jun 30, 2022 | 60,894.00 |
| Mar 31, 2022 | -172,834.00 |
| Dec 31, 2021 | -110,842.00 |
| Sep 30, 2021 | -142,290.00 |
| Jun 30, 2021 | 65,161.00 |
| Mar 31, 2021 | -171,816.00 |
| Dec 31, 2020 | 1.19 Mn |
| Sep 30, 2020 | -139,319.00 |
| Jun 30, 2020 | -1.01 Mn |
| Mar 31, 2020 | 65,511.00 |
| Dec 31, 2019 | -24.77 Mn |
| Sep 30, 2019 | -400,227.00 |
| Jun 30, 2019 | -556,069.00 |
| Mar 31, 2019 | -232,951.00 |